The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology.
Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in over 30 biotechnology and medical device companies since 2002, including MAKO Surgical and two focused ultrasound companies – HistoSonics and Sound Blade Medical.
Prior to his investing career, Mr. Brunk had an entrepreneurial background, founding and serving in a variety of management and board capacities at several venture capital–funded healthcare companies. He was a principal in the healthcare practice at Boston Consulting Group and a member of the investment banking group at Credit Suisse First Boston.
“Gerry brings deep experience across biotech, medical devices, and healthcare innovation, including engagement with focused ultrasound companies,” said Foundation Chairman Neal F. Kassell, MD. “His knowledge and network will strengthen the Foundation’s ability to accelerate progress and ultimately help patients benefit from this technology sooner.”
He also serves on the investment committee of the Seed Fund at the University of Virginia, on the review board of the Ivy Foundation Biomedical Innovation Fund, on the board of directors of Virginia Bio, and as a mentor for the Stanford Mussallem Center for Biodesign.
Mr. Brunk holds a master of business administration from Stanford Graduate School of Business and a bachelor of arts from the University of Virginia.
“I’ve seen firsthand how focused ultrasound can reshape treatment paradigms when the right science, leadership, and ecosystem come together,” said Mr. Brunk. “The Foundation plays a pivotal role in advancing that mission, and I’m excited to contribute to its efforts to broaden adoption and bring these therapies to patients who need them.”